Cordarone scandal: Biogaran laboratories condemned. Interview with the complainant, Jean Pierre Dubourdieu

by time news

2023-04-27 19:00:00

ESSENTIAL MAINTENANCE – On March 29, 2023, the Court of Cassation ruled in favor of Jean-Pierre Dubourdieu, in the context of the trial which opposed him to the pharmaceutical laboratories Biogaran and to Dr Barrière, cardiologist.

The father of this aeronautical technician died in June 2010 of progressive asphyxia. His cardiologist had prescribed Cordarone, a drug belonging to class III of the family of antiarrhythmics.

Biogaran laboratories and Dr. Barrière were ordered to pay more than 140,000 euros in damages to Jean-Pierre Dubourdieu, for not having sufficiently informed his father about the risks he was taking with this drug.

According to the plaintiff, the laboratories changed the leaflet during this case to better inform patients about the adverse effects of this product.

Our guest regrets that Dr. Barrière was not condemned for having continued to prescribe Cordarone preventively, but simply for a lack of information to the patient. He also regrets that Flecaine (Flecainide) was not prescribed, this drug would have been, according to him, a much less dangerous substitute than Corderone, in particular for long-term preventive treatment.

If Corderone has proven to be toxic (it can cause pulmonary fibrosis), the drug is still legally prescribed.

Jean-Pierre Bourdieu returns in this interview to the dishonesty in his eyes of the representatives of the Biogaran laboratories during these 13 years of trial. Biogaran is the generic drugs subsidiary of Servier Laboratories, which were responsible for the production of Pick. This drug has already caused a scandal with Servier being fined 2.7 million euros for “aggravated deception” et “manslaughter and manslaughter”.

“Citizens can no longer trust laboratories today”, confirms our guest.

#Cordarone #scandal #Biogaran #laboratories #condemned #Interview #complainant #Jean #Pierre #Dubourdieu

You may also like

Leave a Comment